 |
|
 |
Diseases |
|
|
Autoimmune Overview - Market Continues To Prosper
Commercial Insight
Publication Date December 2007
Publisher Datamonitor
Product Type Report
Pages 285
ISBN Number not applicable
Product Code DAT1122
|
|
|
Summary
Introduction
The autoimmune disease market will be rapidly growing due to a high number of competitive brands currently on the market and a full pipeline. Company strategies include expanding the treatment algorithm by pursuing approval for 'early' disease stages, launching easy-to-use devices to make up for downsides of injectable drugs, and developing fully human monoclonal antibodies as follow-on products.
Scope
- Indication based forecasts for the top autoimmune brands and significant pipeline drugs
- Assessment of indication-specific drivers and resistors likely to impact the market
- Future market outlook for individual products taking into account key market events, and competitor launch dates
- Market overview by indication, mechanism of action and geographical area with value analysis of clinical and commercial factors underlying performance
Highlights
In 2006, the TNF-inhibitors were by far the highest selling mechanism of action in the autoimmune market, across all seven major markets. This group of products was very popular in the US especially, with sales of $6.5 billion accounting for 66% of the market.
In the US, rheumatoid arthritis and multiple sclerosis both had a large share of the sales, 44% ($4.4 billion) and 32% (almost $3.2 billion), respectively. Psoriasis/psoriatic arthritis sales and Crohn's disease sales were lower compared to the top two indications, with sales of $1.2 billion (12%) and $722m (7%), respectively.
Remicade was the second highest-selling drug in the seven major markets of the brands evaluated in this report with sales of $3,130m in 2006. Datamonitor expects this to decrease over the next 10 years mainly due to the launch of follow-on humanized TNF-inhibitor golimumab, which is forecast to take the majority of its share from Remicade.
Reasons to Purchase
- Identify key opportunities and threats that will impact the use and uptake of new and existing products
- Quantify the future size and scope of the autoimmune market and predict the future performance of key compounds
- Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development
|
Content
- Introduction
- The Autoimmune Disease Market Will Be Rapidly Growing Due To A High Number Of Competitive Brands Currently On The Market And A Full Pipeline. Company Strategies Include Expanding The Treatment Algorithm By Pursuing Approval For 'Early' Disease Stages, Launching Easy-To-Use Devices To Make Up For Downsides Of Injectable Drugs, And Developing Fully Human Monoclonal Antibodies As Follow-On Products.
- Scope
- Indication Based Forecasts For The Top Autoimmune Brands And Significant Pipeline Drugs Assessment Of Indication-Specific Drivers And Resistors Likely To Impact The Market Future Market Outlook For Individual Products Taking Into Account Key Market Events, And Competitor Launch Dates Market Overview By Indication, Mechanism Of Action And Geographical Area With Value Analysis Of Clinical And Commercial Factors Underlying Performance
- Highlights
- In 2006, The Tnf-Inhibitors Were By Far The Highest Selling Mechanism Of Action In The Autoimmune Market, Across All Seven Major Markets. This Group Of Products Was Very Popular In The Us Especially, With Sales Of $6.5 Billion Accounting For 66% Of The Market. In The Us, Rheumatoid Arthritis And Multiple Sclerosis Both Had A Large Share Of The Sales, 44% ($4.4 Billion) And 32% (Almost $3.2 Billion), Respectively. Psoriasis/Psoriatic Arthritis Sales And Crohn's Disease Sales Were Lower Compared To The Top Two Indications, With Sales Of $1.2 Billion (12%) And $722m (7%), Respectively. Remicade Was The Second Highest-Selling Drug In The Seven Major Markets Of The Brands Evaluated In This Report With Sales Of $3,130m In 2006. Datamonitor Expects This To Decrease Over The Next 10 Years Mainly Due To The Launch Of Follow-On Humanized Tnf-Inhibitor Golimumab, Which Is Forecast To Take The Majority Of Its Share From Remicade.
- Reasons To Purchase
- Identify Key Opportunities And Threats That Will Impact The Use And Uptake Of New And Existing Products Quantify The Future Size And
- Scope Of The Autoimmune Market And Predict The Future Performance Of Key Compounds Understand And Capitalize On Clinical Unmet Needs In The Market, Either Through Lifecycle Management Of Marketed Drugs Or New Product Development.
|
|
|
